ClinicalTrials.gg
TerminatedNCT03379363Updated Jul 30, 2019

Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

An observational study in Hypercortisolism and Cushing Syndrome, sponsored by Corcept Therapeutics. Terminated at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2019-07-30.

Sponsored by Corcept Therapeutics · Observational

Why this study was terminated
Insufficient number of patients

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
2
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Cushing Syndrome by Corcept Therapeutics — none open to participants now, 1 under way, none of them phase 3. Cushing Syndrome · Corcept Therapeutics.

Started
2017
the only one that year
Observational
5 of 16
none open now
Registered
9th of 16
by date

Among the 16 studies in Cushing Syndrome by Corcept Therapeutics, this one is the only one that started in 2017, is one of 5 observational ones, and was the 9th registered.

Cushing Syndrome

123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.

Browse Cushing Syndrome studies →

Open to participants now

None of the 16 studies in Cushing Syndrome by Corcept Therapeutics is open now. The open studies under Cushing Syndrome, anywhere →

Who these studies take

Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Cushing Syndrome by Corcept Therapeutics as a file.
02

Study summary

This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.

Read the detailed description

This retrospective chart review study seeks to collect data from pediatric patients treated with Korlym (mifepristone) to help provide clinicians with some insight on the potential role of mifepristone in the treatment of pediatric patients with Cushing syndrome.

Only sites that have been identified to have patients appropriate for this protocol will be invited to participate and contribute data on their patients

Data to be collected from a retrospective chart review will include:

  • Patient demographics
  • Medical history
  • Pre and post treatment clinical assessments and laboratory results
  • Radiologic findings (if available)
  • Adverse events

Data will be collected for all follow-up visits, up until the most recent encounter prior to IRB approval.

03

Conditions studied

  • Hypercortisolism
  • Cushing Syndrome

Browse trials for

Keywords

  • cushing syndrome, hypercortisolism
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients who have been treated with Korlym for Cushing's syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatrics (age≤21 years) at time Korlym initiation
  • Considered to have a diagnosis of endogenous Cushing's syndrome by the healthcare provider
  • Received at least one dose of Korlym
  • Availability of pre-treatment (baseline) and follow-up data

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
2 participants (actual)
Patient registry
No

Groups and cohorts

  • Pediatric Cushing Syndrome Patients

    Pediatrics patients with endogenous Cushing syndrome who received at least one dose of Korlym

06

What researchers measure

Primary outcomes

  1. Drug utilization patterns as assessed by chart review

    The retrospective review would analyze the drug utilization patterns of pediatric patients treated with Korlym

    Time frame: Length of Korlym therapy, up to 5 years

Secondary outcomes

  1. Weight as assessed by chart review

    The retrospective review would analyze changes in Weight (in kg) in pediatric patients treated with Korlym

    Time frame: Length of Korlym therapy, up to 5 years

  2. Blood Pressure as assessed by chart review

    The retrospective review would analyze changes in Blood Pressure (in mmHg) in pediatric patients treated with Korlym

    Time frame: Length of Korlym therapy, up to 5 years

07

Study locations

1 site
  • Corcept Therapeutics
    Menlo Park, California 94025, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Feb 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2017
First posted
Dec 20, 2017
StartActual
Sep 18, 2017
Primary completionActual
Feb 12, 2018
CompletionActual
Feb 12, 2018
Last update
Jul 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03379363
Responsible party
Sponsor
First posted
Dec 20, 2017
Start date
Sep 18, 2017
Primary completion
Feb 12, 2018
Completion
Feb 12, 2018
Last update
Jul 30, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion